These findings have substantial implications for cancer therapy, as IDH inhibitors successfully use 2-HG suppression to hinder IDH-mutant glioma cells, which are more sensitive to glutaminase inhibitors [64]. The gene discussed is IDH1; the disease is central nervous system cancer.